Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Authors:
Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P and de Wit R.
Publication type:
Journal article
Publication name:
European Urology Oncology
Citation:
Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P and de Wit R. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. European Urology Oncology. 2018.
